[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355153-105":59,"doc-detail-355153-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cep55-promotes-prostate-cancer-progression-tpx2-dependent-activation-of-aurka-pi3k-akt-signaling-and-inhibition-of-ferroptosis","CEP55 promotes prostate cancer progression - TPX2-dependent activation of AURKA - PI3K - AKT signaling and inhibition of ferroptosis","","Research article examining how centrosomal protein 55 (CEP55) drives prostate cancer (PCa) progression by modulating TPX2-dependent activation of the AURKA–PI3K–AKT signaling axis and controlling ferroptosis. CEP55 expression is assessed in clinical samples and cell lines, and functional effects on growth, invasion, and tumorigenesis are tested after CEP55 overexpression or knockdown. Mechanistic work links CEP55–TPX2 interaction to increased SLC7A11/GPX4, reduced lipid ROS, and ferroptosis resistance, reversed by CAM2602.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cep55-promotes-prostate-cancer-progression-tpx2-dependent-activation-of-aurka-pi3k-akt-signaling-and-inhibition-of-ferroptosis/355153/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cep55-promotes-prostate-cancer-progression-tpx2-dependent-activation-of-aurka-pi3k-akt-signaling-and-inhibition-of-ferroptosis/355153.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How was CEP55 expression evaluated in prostate cancer samples and cells?","Question",{"text":112,"@type":113},"CEP55 levels were measured in clinical samples and cell lines using bioinformatics analysis, quantitative RT–PCR, and Western blot.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What mechanism links CEP55 to ferroptosis resistance in prostate cancer?",{"text":117,"@type":113},"CEP55 interacts with TPX2 to activate AURKA–PI3K–AKT signaling, increasing SLC7A11 and GPX4 expression while reducing lipid reactive oxygen species accumulation, which confers resistance to ferroptosis.",{"name":119,"@type":110,"acceptedAnswer":120},"Which intervention reversed the CEP55-related effects on the TPX2–AURKA axis?",{"text":121,"@type":113},"Pharmacological inhibition of the TPX2–AURKA interaction with CAM2602 reversed the signaling activation and ferroptosis-related changes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355153,1790197609,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","RESEARCH ARTICLE  \nCEP55 promotes prostate cancer progression via  \nTPX2-dependent activation of AURKA–PI3K–AKT signaling and inhibition of ferroptosis  \nReceived for publication, September 4, 2025, and in revised form, January 16, 2026 Published, Papers in Press, January 28, 2026 [https://doi.org/10.1016/j.jbc.2026.1](https://doi.org/10.1016/j.jbc.2026.1)11218  \nLizhe Xu 1,‡, Jinzhuo Ning 1,‡, Jinrun Wang1,‡, Pengcheng Jiang1, Xu Zhang1,2,*, and Fan Cheng 1, *  \nFrom the 1Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, PR China; 2Department of Urology, Chinese PLA General Hospital, Beijing, PR China  \nReviewed by members of the JBC Editorial Board. Edited by Paul Shapiro  \nProstate cancer (PCa) is a highly heterogeneous malignancy with variable clinical outcomes. Centrosomal protein 55 (CEP55) has been involved in the progression of multiple cancers, but its function in PCa is still largely uncharacterized. CEP55 expression was evaluated in clinical samples and cell lines via bioinformatics analysis, quantitative RT–PCR, and Western blot. Functional assessments, such as wound healing, Cell Counting Kit-8, and Transwell invasion, were carried out to evaluate the impact of CEP55 upregulation or knockdown on PCa cell growth and metastasis. Coimmunoprecipitation was utilized to observe the interaction between CEP55 and TPX2 microtubule nucleation factor. The role of CEP55 in ferroptosis regulation was assessed by measuring IC50 values of ferroptosis inducers, lipid reactive oxygen species levels, and the expression of ferroptosis-correlated proteins, solute carrier family 7 member 11 (SLC7A11) and glutathione peroxidase 4 (GPX4). Xenograft tumor models were created to evaluate the in vivo effects of CEP55 suppression. CEP55 showed a significant upregulation in PCa tissues and cell lines. CEP55 overexpression was linked to advanced clinicopathological features and poor prognosis. Mechanistically, CEP55 interacted with TPX2 to activate the aurora kinase A (AURKA)–PI3K–AKT signaling cascade. This activation led to increased expression of SLC7A11 and GPX4, reduced lipid reactive oxygen species accumulation, and conferred resistance to ferroptosis. Pharmacological inhibition ofthe TPX2–AURKA interaction with CAM2602 reversed these effects. In vivo trials illustrated that CEP55 knockdown inhibited tumor growth and downregulated key proteins in the TPX2–AURKA–PI3K–AKT and ferroptosis resistance pathway. Our findings demonstrate that CEP55 enhances PCa progression by stimulating the TPX2–AURKA–PI3K–AKT signaling pathway and inhibiting ferroptosis. Targeting this axis may represent a potential therapeutic approach for PCa.  \nProstate cancer (PCa) is one of the most common malignancies in males globally, involved substantially in cancerassociated mortality and morbidity (1). Current early  \n‡ These authors contributed equally to this work.  \n* For correspondence: Xu Zhang, [xzhang301@163.com](xzhang301@163.com); Fan Cheng, [urology1969@aliyun.com](urology1969@aliyun.com).  \ndetection primarily relies on prostate-specific antigen (PSA) testing, digital rectal examination, and increasingly, advanced imaging techniques, such as multiparametric MRI (2). Standard treatments for localized disorder comprise active surveillance, radical prostatectomy, and radiotherapy, whereas metastatic PCa is managed with androgen deprivation therapy, chemotherapy, and novel hormonal agents, like abiraterone and enzalutamide (3). Despite these advances, the molecular heterogeneity of PCa—ranging from indolent to highly aggressive forms—poses persistent challenges in prognosis and therapeutic decision making (4). A deeper comprehension of the underlying mechanisms driving tumor initiation, progression, and therapeutic resistance is therefore urgently needed to refine clinical strategies and improve patient outcomes.  \nCentrosomal protein 55 (CEP55), located on chromosome 10q23.33, is a crucial component of the midbody during cyt","cbCaif4EnNbuPdHZ","https://ap.wps.com/l/cbCaif4EnNbuPdHZ","pdf",16861538,17,"English","# Introduction\n## CEP55 in cancer and rationale for PCa\n# Methods and Experimental Approach\n## Expression evaluation and functional assays\n## Interaction studies and ferroptosis readouts\n## Xenograft tumor models\n# Results and Mechanistic Findings\n## CEP55 upregulation and clinical correlation\n## CEP55–TPX2–AURKA–PI3K–AKT signaling activation\n## Ferroptosis inhibition and CAM2602 reversal\n# Conclusion\n## Therapeutic targeting of the CEP55 axis","[{\"question\":\"How was CEP55 expression evaluated in prostate cancer samples and cells?\",\"answer\":\"CEP55 levels were measured in clinical samples and cell lines using bioinformatics analysis, quantitative RT–PCR, and Western blot.\"},{\"question\":\"What mechanism links CEP55 to ferroptosis resistance in prostate cancer?\",\"answer\":\"CEP55 interacts with TPX2 to activate AURKA–PI3K–AKT signaling, increasing SLC7A11 and GPX4 expression while reducing lipid reactive oxygen species accumulation, which confers resistance to ferroptosis.\"},{\"question\":\"Which intervention reversed the CEP55-related effects on the TPX2–AURKA axis?\",\"answer\":\"Pharmacological inhibition of the TPX2–AURKA interaction with CAM2602 reversed the signaling activation and ferroptosis-related changes.\"}]","CEP55 promotes prostate cancer progression - TPX2-dependent activation of AURKA - PI3K - AKT signaling and inhibition of ferroptosis | PDF",1790116360,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f5739d13c6b465095dfeb2c7bf00bcb.webp",983,1296,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e0aa0c1ef8726f6b7152ab5dca90c02.webp",982,1294,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4966e5499155b23cc9af3c1a019482b8.webp",981,1293,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/70d990bc2df1016c86e7b730eb841917.webp",980,1292]